N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 3 ClinicalTrials.gov

Study of Olverembatinib (HQP1351) in Patients With CML-CP

Sponsor: Ascentage Pharma Group Inc. • ClinicalTrials.gov ID: NCT06423911

Registry updated: 2026-09-15
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Study comparing efficacy and safety of olverembatinib (investigational arm) vs. bosutinib (control arm) in patients with CML-CP (Part A). Study will also evaluate efficacy and safety of olverembatinib (single-arm) in CML-CP patients with T315I mutation (Part B). Patients who meet ELN 2025 failure criteria while receiving bosutinib in Part A may be able to receive olverembatinib in crossover follow-on study.

Interventions

  • olverembatinib (Drug)
    olverembatinib QOD
  • Bosutinib (Drug)
    Bosutnib QD

Eligibility criteria

Inclusion Criteria Patients eligible for inclusion in this study must meet all of the following criteria: 1. Age ≥ 18 years old 2. Diagnosis of CML-CP 3. Part A: Previously treated with at least two approved TKIs; Part B: T315I mutation at screening and previously treated with at least one approved TKI, with no other effective and/or tolerable therapies available 4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2 5. Patient has adequate organ function Exclusion Criteria Patients eligible for this study must not meet any of the following criteria: 1. For Part A only: T315I or V299L mutation at any time prior to starting study treatment 2. Active infection that requires systemic drug therapy 3. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter absorption of study drugs 4. Previous treatment with or known / suspected hypersensitivity to olverembatinib or any of its excipients 5. Previous treatment with or known / suspected hypersensitivity to bosutinib or any of its excipients 6. Pregnant or nursing (lactating) women

Conditions

Chronic Myeloid Leukemia CML CML, Chronic Phase

Locations

  • Ascentage Investigative Site #1044 — Birmingham, Alabama, United States
  • Ascentage Investigative Site #1112 — Anchorage, Alaska, United States
  • Ascentage Investigative Site #1111 — Goodyear, Arizona, United States
  • Ascentage Investigative Site #1062 — Duarte, California, United States
  • Ascentage Investigative Site #1099 — Irvine, California, United States
  • Ascentage Investigative Site #1075 — La Jolla, California, United States
  • Ascentage Investigative Site #1100 — Long Beach, California, United States
  • Ascentage Investigative Site #1059 — Los Angeles, California, United States
  • Ascentage Investigative Site #1121 — Sacramento, California, United States
  • Ascentage Investigative Site #1109 — Upland, California, United States
  • Ascentage Investigative Site #1045 — Augusta, Georgia, United States
  • Ascentage Investigative Site #1110 — Newnan, Georgia, United States
  • Ascentage Investigative Site #1055 — Chicago, Illinois, United States
  • Ascentage Investigative Site #1095 — Decatur, Illinois, United States
  • Ascentage Investigative Site #1069 — Indianapolis, Indiana, United States
  • Ascentage Investigative Site #1065 — Wichita, Kansas, United States
  • Ascentage Investigative Site #1084 — Lexington, Kentucky, United States
  • Ascentage Investigative Site #1058 — Louisville, Kentucky, United States
  • Ascentage Investigative Site #1801 — Baltimore, Maryland, United States
  • Ascentage Investigative Site #1056 — Detroit, Michigan, United States
  • Ascentage Investigative Site #1023 — Detroit, Michigan, United States
  • Ascentage Investigative Site #1088 — St Louis, Missouri, United States
  • Ascentage Investigative Site #1097 — Lincoln, Nebraska, United States
  • Ascentage Investigative Site #1066 — Las Vegas, Nevada, United States
  • Ascentage Investigative Site #1113 — Reno, Nevada, United States
  • Ascentage Investigative Site #1064 — Hackensack, New Jersey, United States
  • Ascentage Investigative Site #1054 — Morristown, New Jersey, United States
  • Ascentage Investigative Site #1098 — New Brunswick, New Jersey, United States
  • Ascentage Investigative Site #1072 — Albuquerque, New Mexico, United States
  • Ascentage Investigative Site #1068 — Rochester, New York, United States
  • Ascentage Investigative Site #1053 — Shirley, New York, United States
  • Ascentage Investigative Site #1160 — Stony Brook, New York, United States
  • Ascentage Investigative Site #1019 — Greenville, North Carolina, United States
  • Ascentage Investigative Site #1043 — Morrisville, North Carolina, United States
  • Ascentage Investigative Site #1173 — Cleveland, Ohio, United States
  • Ascentage Investigative Site #1096 — Cleveland, Ohio, United States
  • Ascentage Investigative Site #1174 — Mayfield Heights, Ohio, United States
  • Ascentage Investigative Site #1139 — Portland, Oregon, United States
  • Ascentage Investigative Site #1057 — Philadelphia, Pennsylvania, United States
  • Ascentage Investigative Site #1022 — Pittsburgh, Pennsylvania, United States
  • Ascentage Investigative Site #1063 — Chattanooga, Tennessee, United States
  • Ascentage Investigative Site #1089 — Nashville, Tennessee, United States
  • Ascentage Investigative Site #1051 — Amarillo, Texas, United States
  • Ascentage Investigative Site #1036 — Austin, Texas, United States
  • Ascentage Investigative Site #1501 — Houston, Texas, United States
  • Ascentage Investigative Site #1050 — Virginia Beach, Virginia, United States
  • Ascentage Investigative Site #1136 — Edmonds, Washington, United States
  • Ascentage Investigative Site #1135 — Issaquah, Washington, United States
  • Ascentage Investigative Site #1806 — Seattle, Washington, United States
  • Ascentage Investigative Site #1510 — Seattle, Washington, United States
  • Ascentage Investigative Site #2107 — Campbelltown, New South Wales, Australia
  • Ascentage Investigative Site #2105 — Liverpool, New South Wales, Australia
  • Ascentage Investigative Site #2115 — Adelaide, South Australia, Australia
  • Ascentage Investigative Site #2106 — Perth, Western Australia, Australia
  • Ascentage Investigative Site #5211 — Anderlecht, Belgium
  • Ascentage Investigative Site #5212 — Gilly, Belgium
  • Ascentage Investigative Site #5208 — Kortrijk, Belgium
  • Ascentage Investigative Site #5209 — Roeselare, Belgium
  • Ascentage Investigative Site #5210 — Yvoir, Belgium
  • Ascentage Investigative Site #8004 — Toronto, Canada
  • Ascentage Investigative Site #5037 — Amiens, France
  • Ascentage Investigative Site #5015 — Bobigny, France
  • Ascentage Investigative Site #5017 — Nice, France
  • Ascentage Investigative Site #5016 — Rouen, France
  • Ascentage Investigative Site #5023 — Toulouse, France
  • Ascentage Investigative Site #5708 — Berlin, Germany
  • Ascentage Investigative Site #5709 — Dresden, Germany
  • Ascentage Investigative Site #9118 — Bangalore, India
  • Ascentage Investigative Site #9120 — Haryāna, India
  • Ascentage Investigative Site #9102 — Haryāna, India
  • Ascentage Investigative Site #9110 — Hyderabad, India
  • Ascentage Investigative Site #9116 — Kolkata, India
  • Ascentage Investigative Site #9115 — Kolkata, India
  • Ascentage Investigative Site #9101 — New Delhi, India
  • Ascentage Investigative Site #9103 — New Delhi, India
  • Ascentage Investigative Site #9119 — Pune, India
  • Ascentage Investigative Site #9113 — Thiruvananthapuram, India
  • Ascentage Investigative Site #5535 — Bologna, Italy
  • Ascentage Investigative Site #5534 — Candiolo, Italy
  • Ascentage Investigative Site #5527 — Catania, Italy
  • Ascentage Investigative Site #5523 — Lecce, Italy
  • Ascentage Investigative Site #5529 — Meldola, Italy
  • Ascentage Investigative Site #5537 — Messina, Italy
  • Ascentage Investigative Site #5553 — Milan, Italy
  • Ascentage Investigative Site #5530 — Naples, Italy
  • Ascentage Investigative Site #5524 — Novara, Italy
  • Ascentage Investigative Site #5525 — Padova, Italy
  • Ascentage Investigative Site #5526 — Pisa, Italy
  • Ascentage Investigative Site #5528 — Roma, Italy
  • Ascentage Investigative Site #5522 — Roma, Italy
  • Ascentage Investigative Site #5510 — Roma, Italy
  • Ascentage Investigative Site #5552 — Torino, Italy
  • Ascentage Investigative Site #5521 — Torino, Italy
  • Ascentage Investigative Site #5536 — Varese, Italy
  • Ascentage Investigative Site #8101 — Ehime, Japan
  • Ascentage Investigative Site #8102 — Kyoto, Japan
  • Ascentage Investigative Site #8112 — Okayama, Japan
  • Ascentage Investigative Site #8105 — Osaka, Japan
  • Ascentage Investigative Site #8106 — Sapporo, Japan
  • Ascentage Investigative Site #8107 — Sapporo, Japan
  • Ascentage Investigative Site #8109 — Tochigi, Japan
  • Ascentage Investigative Site #8114 — Tokyo, Japan
  • Ascentage Investigative Site #8117 — Tokyo, Japan
  • Ascentage Investigative Site #8110 — Tokyo, Japan
  • Ascentage Investigative Site #8104 — Yamagata, Japan
  • Ascentage Investigative Site #8103 — Yamanashi, Japan
  • Ascentage Investigative Site #4213 — Gdansk, Poland
  • Ascentage Investigative Site #4212 — Gdansk, Poland
  • Ascentage Investigative Site #4207 — Katowice, Poland
  • Ascentage Investigative Site #4209 — Krakow, Poland
  • Ascentage Investigative Site #4211 — Lodz, Poland
  • Ascentage Investigative Site #4214 — Torun, Poland
  • Ascentage Investigative Site #4206 — Warsaw, Poland
  • Ascentage Investigative Site #4210 — Wałbrzych, Poland
  • Ascentage Investigative Site #3227 — Moscow, Russia
  • Ascentage Investigative Site #3228 — Saint Petersburg, Russia
  • Ascentage Investigative Site #3213 — Saint Petersburg, Russia
  • Ascentage Investigative Site #3212 — Saint Petersburg, Russia
  • Ascentage Investigative Site #6602 — Singapore, Singapore
  • Ascentage Investigative Site #6601 — Singapore, Singapore
  • Ascentage Investigative Site #8206 — Busan, South Korea
  • Ascentage Investigative Site #8207 — Busan, South Korea
  • Ascentage Investigative Site #8204 — Gyeonggi-do, South Korea
  • Ascentage Investigative Site #8201 — Seoul, South Korea
  • Ascentage Investigative Site #8202 — Seoul, South Korea
  • Ascentage Investigative Site #8205 — Seoul, South Korea
  • Ascentage Investigative Site #8203 — Seoul, South Korea
  • Ascentage Investigative Ste #8208 — Uijeongbu-si, South Korea
  • Ascentage Investigative Site #6015 — Badalona, Spain
  • Ascentage Investigative Site #6020 — Barcelona, Spain
  • Ascentage Investigative Site #6047 — Elche, Spain
  • Ascentage Investigative Site #6014 — L'Hospitalet de Llobregat, Spain
  • Ascentage Investigative Site #6035 — Madrid, Spain
  • Ascentage Investigative Site #6013 — Madrid, Spain
  • Ascentage Investigative Site #6033 — Madrid, Spain
  • Ascentage Investigative Site #6011 — Madrid, Spain
  • Ascentage Investigative Site #6032 — Madrid, Spain
  • Ascentage Investigative Site #6037 — Majadahonda, Spain
  • Ascentage Investigative Site #6012 — Málaga, Spain
  • Ascentage Investigative Site #6039 — Málaga, Spain
  • Ascentage Investigative Site #6051 — Murcia, Spain
  • Ascentage Investigative Site #6036 — Ourense, Spain
  • Ascentage Investigative Site #6038 — Valencia, Spain
  • Ascentage Investigative Site #6041 — Zaragoza, Spain
  • Ascentage Investigative Site #9216 — Adapazarı, Turkey (Türkiye)
  • Ascentage Investigative Site #9218 — Ankara, Turkey (Türkiye)
  • Ascentage Investigative Site #9204 — Ankara, Turkey (Türkiye)
  • Ascentage Investigative Site #9215 — Battalgazi, Turkey (Türkiye)
  • Ascentage Investigative Site #9217 — Çankaya, Turkey (Türkiye)
  • Ascentage Investigative Site #9219 — Istanbul, Turkey (Türkiye)
  • Ascentage Investigative Site #9205 — Kepez, Turkey (Türkiye)
  • Ascentage Investigative Site #9208 — Mezitli, Turkey (Türkiye)
  • Ascentage Investigative Site #9213 — Ortahisar, Turkey (Türkiye)
  • Ascentage Investigative Site #9214 — Samsun, Turkey (Türkiye)
  • Ascentage Investigative Site #9212 — Yenimahalle, Turkey (Türkiye)
  • Ascentage Investigative Site #7017 — Aberdeen, United Kingdom
  • Ascentage Investigative Site #7036 — Birmingham, United Kingdom
  • Ascentage Investigative Site #7021 — Boston, United Kingdom
  • Ascentage Investigative Site #7037 — Bradford, United Kingdom
  • Ascentage Investigative Site #7035 — Liverpool, United Kingdom
  • Ascentage Investigative Site #7016 — London, United Kingdom
  • Ascentage Investigative Site #7015 — London, United Kingdom
  • Ascentage Investigative Site #7018 — Newport, United Kingdom
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record